Kelonia Therapeutics acquired by Eli Lilly and Company
Eli Lilly and Company agreed to acquire Kelonia Therapeutics, a US therapeutics brand, on Apr 20, 2026.
Preliminary: The announcement date is not yet independently verified.
Transaction summary
- Target
- Kelonia Therapeutics
- Acquirer
- Eli Lilly and Company
- Seller
- -
- Announced
- 2026-04-20(unverified)
- Geography
- United States
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-13
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Enterprise value is unavailable.
Source summary
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies - PR Newswire
ConfirmedPR Newswire headline reports that Lilly is to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies; published April 20, 2026.
Open sourceContinue your research
Related transaction comps
4E Therapeutics acquired by Eli Lilly and Company
2026-06-16 · Confirmed
View transaction → Same buyer / investorAtaiBeckley acquired by Eli Lilly and Company
- · Confirmed
View transaction → BiotechEdgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → BiotechMyricx Bio acquired by Novartis
2026-07-06 · Confirmed
View transaction →